Konstantin Dobrenkov
- Oncology top 5%
- Immunology top 10%
- Molecular Biology
- Genetics top 10%
- Biomedical Engineering
- Co-authors
- Nai‐Kong V. CheungVladimir PonomarevMichel SadelainMatthias T. StephanRenier J. BrentjensAlex H. ChangGlenn HellerIrina Ostrovnaya
- Topics
- Cancer Immunotherapy and Biomarkers (10 papers)Neuroblastoma Research and Treatments (7 papers)Immunotherapy and Immune Responses (7 papers)
- Cited by
- OncologyImmunologyGenetics
- Partner nations
- United StatesIsraelAustralia
In The Last Decade
Konstantin Dobrenkov
27 papers receiving 815 citations
Peers
Comparison fields: 5 of 55
- Oncology 559
- Immunology 363
- Molecular Biology 235
- Genetics 190
- Biomedical Engineering 131
Countries citing papers authored by Konstantin Dobrenkov
This map shows the geographic impact of Konstantin Dobrenkov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Konstantin Dobrenkov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Konstantin Dobrenkov more than expected).
Fields of papers citing papers by Konstantin Dobrenkov
This network shows the impact of papers produced by Konstantin Dobrenkov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Konstantin Dobrenkov. The network helps show where Konstantin Dobrenkov may publish in the future.
Co-authorship network of co-authors of Konstantin Dobrenkov
This figure shows the co-authorship network connecting the top 25 collaborators of Konstantin Dobrenkov. A scholar is included among the top collaborators of Konstantin Dobrenkov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Konstantin Dobrenkov. Konstantin Dobrenkov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 7 | |
| 2 | 19 | |
| 3 | 10 | |
| 4 | 46 | |
| 5 | 47 | |
| 6 | 3 | |
| 7 | 20 | |
| 8 | 14 | |
| 9 | 104 | |
| 10 | 2 | |
| 11 | 66 | |
| 12 | 5 | |
| 13 | 2 | |
| 14 | 16 | |
| 15 | 51 | |
| 16 | 12 | |
| 17 | 67 | |
| 18 | 15 | |
| 19 | 237 | |
| 20 | Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells. | 10 |
About Konstantin Dobrenkov
Konstantin Dobrenkov is a scholar working on Oncology, Neurology and Immunology, having authored 28 papers that have together received 829 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (10 papers), Neuroblastoma Research and Treatments (7 papers) and Immunotherapy and Immune Responses (7 papers). The work is most often cited by research in Oncology (559 citations), Immunology (363 citations) and Genetics (190 citations). Konstantin Dobrenkov has collaborated with scholars based in United States, Israel and Australia. Frequent co-authors include Nai‐Kong V. Cheung, Vladimir Ponomarev, Michel Sadelain, Matthias T. Stephan, Renier J. Brentjens, Alex H. Chang, Glenn Heller, Irina Ostrovnaya, Irene Y. Cheung and Jessie Gu. Their work appears in journals such as Nature Medicine, Journal of Clinical Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.